Revascularization and amputation-free survival
amputation, Diabetic
No limb revascularization was necessary for the auto-BM-MNC (0 of 7) and allo-WJ-MSC (0 of 7) groups, while two participants of the placebo group had to receive revascularization (2 of 10).The amputation-free survival analysis between auto-BM-MNC and allo-WJ-MSC versus placebo groups showed that patients with CLTI treated with auto-BM-MNC and allo-WJ-MSCs conserved 100% of their limb after 12 months of follow-up compared to the placebo group, where 60% of participants underwent limb amputation at different times (Fig. Diabetic patients with CTLI conserved their limbs after the treatment with auto-BM-MNC or allo-WJ-MSCs. Amputation-free survival analysis showed that patients with CLTI treated with auto-BM-MNC and allo-WJ-MSCs conserved 100% of their limbs during 12 months of the follow-up compared to the placebo group, where 60% of participants underwent limb amputation at different times. Auto-BM-MNC, autologous bone marrow mononuclear cell and allo-WJ-MSCs, allogenic Wharton jelly-derived mesenchymal stem cellsAmputation-free survival analysis was adjusted by age and baseline hemoglobin A1c; however, these variables did not interfere with the outcome.